Urovant Ltd. (UROV) Sees Clear Path To Vibregron Approval - Cowen

Cowen analyst Rita Baral reiterated an Outperform rating and $25.00 price target on Urovant Ltd. (NASDAQ: UROV) after the company announced positive Ph3 vibegron data in OAB. Vibegron met both coprimary endpoints to significance with good safety and tolerability, allowing a clear path to
approval.

The analyst stated "Vibegron also met all specified secondary endpoints, including urgency. We think the dataset will set up a compelling marketing strategy based on a superior clinical profile to generic AChIs and Myrbetriq".

For an analyst ratings summary and ratings history on Urovant Ltd. click here. For more ratings news on Urovant Ltd. click here.

Shares of Urovant Ltd. closed at $11.35 yesterday.

You May Also Be Interested In

• TD Cowen Upgrades DaVita (DVA) to Buy
• Wedbush Upgrades Airbnb Inc. (ABNB) to Outperform 'on Broad Strength & New Initiative Positives'
• JPMorgan Starts Shanghai V-Test Semiconductor (688372:CH) at Overweight